1. Home
  2. FORTY vs DMRA Comparison

FORTY vs DMRA Comparison

Compare FORTY & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Formula Systems (1985) Ltd.

FORTY

Formula Systems (1985) Ltd.

HOLD

Current Price

$117.08

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

HOLD

Current Price

$20.77

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FORTY
DMRA
Founded
1985
2011
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
1998
2020

Fundamental Metrics

Financial Performance
Metric
FORTY
DMRA
Price
$117.08
$20.77
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $46.89
AVG Volume (30 Days)
2.3K
★ 519.7K
Earning Date
11-19-2026
11-05-2026
Dividend Yield
★ 9.68%
N/A
EPS Growth
N/A
★ 121.48
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$36.65
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$102.01
$16.50
52 Week High
$190.56
$34.89

Technical Indicators

Market Signals
Indicator
FORTY
DMRA
Relative Strength Index (RSI) 48.19 40.58
Support Level $109.16 $18.73
Resistance Level $119.68 $26.76
Average True Range (ATR) 1.52 1.36
MACD -0.67 0.16
Stochastic Oscillator 28.17 50.46

Price Performance

Historical Comparison
FORTY
DMRA

About FORTY Formula Systems (1985) Ltd.

Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: